Using Long-Term Data to Guide ALK+ NSCLC Treatment

Panelists explain that long-term results have redefined expectations for disease control, guiding decisions about sequencing and treatment duration. They highlight that deep responses and intracranial protection achieved with newer inhibitors have shifted clinical priorities toward maintaining therapy adherence and minimizing toxicity.

The discussion emphasizes shared decision-making between clinicians and patients. By aligning treatment goals with patient preferences and tolerability, care teams can improve adherence and sustain treatment benefits over time.

Overall, panelists agree that integrating long-term outcomes data into practice helps clinicians anticipate patterns of resistance, personalize follow-up, and design durable treatment strategies that align with evolving patient needs.